Holen Sie sich die Stockscreener-App
23.26
1.15%
-0.27
Handel nachbörslich:
23.26
Pacira Biosciences Inc Aktie (PCRX) Neueste Nachrichten
Pacira BioSciences advances non opioid pain therapies to transform patient care - Traders Union
Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation - Sahm
Pacira BioSciences responds to DOMA director nominations - Investing.com Australia
Pacira BioSciences responds to DOMA director nominations By Investing.com - Investing.com Nigeria
Activist hedge fund pushes Pacira BioSciences to sell itself - The Business Journals
Pacira Faces Board Fight As Activist Investor Criticizes CEO Pay, Missed Earnings - Benzinga
Pacira spends $150M on buybacks as DOMA seeks board seats - Stock Titan
Pacira BioSciences shares rise 2% as activist pushes for CEO removal - Investing.com Canada
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc. - PR Newswire
Pacira BioSciences (NASDAQ:PCRX) Downgraded to "Strong Sell" Rating by Zacks Research - MarketBeat
Liquidity Mapping Around (PCRX) Price Events - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Shareholders to Reach Out - ACCESS Newswire
Pacira BioSciences, Inc. $PCRX Shares Purchased by American Century Companies Inc. - MarketBeat
Earnings Beat: Does Pacira BioSciences Inc have consistent dividend growthQuarterly Profit Review & Accurate Entry/Exit Alerts - baoquankhu1.vn
Pacira (PCRX) Grants Inducement Awards to New Employees - GuruFocus
Pacira BioSciences reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) Presents a Compelling Value Investment Case - ChartMill
Vanguard Group Inc. Trims Holdings in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference - The Manila Times
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2025 Earnings Call Transcript - Insider Monkey
Pacira BioSciences (NASDAQ:PCRX) Stock Price Up 4.6%What's Next? - MarketBeat
PCRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR) - Bitget
Pacira BioSciences (PCRX) Shows Promising Results in Knee Surger - GuruFocus
Pacira BioSciences, Inc. Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry - marketscreener.com
Non-opioid knee pain options show 12-month relief in study - Stock Titan
Pacira BioSciences (PCRX) Valuation Check After Mixed Share Performance And High P/E Multiple - simplywall.st
Assessing Pacira BioSciences (PCRX) Valuation After Recent Share Price Weakness - Yahoo Finance
Wall Street Zen Downgrades Pacira BioSciences (NASDAQ:PCRX) to Buy - MarketBeat
Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down - The Globe and Mail
Pacira BioSciences Q4 Profit Return Tests Bullish Turnaround Narrative - simplywall.st
Pacira BioSciences, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:PCRX) 2026-02-27 - Seeking Alpha
Pacira BioSciences (NASDAQ:PCRX) Shares Gap DownWhat's Next? - MarketBeat
Truist Adjusts Price Target on Pacira Biosciences to $27 From $28, Maintains Buy Rating - marketscreener.com
Pacira BioSciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Pacira BioSciences Q4 Earnings Call Highlights - MarketBeat
Pacira BioSciences Inc (PCRX) Q4 2025 Earnings Call Highlights: - GuruFocus
Pacira BioSciences (NASDAQ:PCRX) Releases Earnings Results, Misses Expectations By $0.28 EPS - MarketBeat
Pacira BioSciences reports fourth quarter and full-year 2025 financial results - marketscreener.com
Pacira Biosciences slips as 2026 revenue guidance, Q4 2025 results disappoint - MSN
Pacira Biosciences Reports Fourth Quarter And Full-Year 2025 Financial Results - TradingView
Pacira (PCRX) Q4 2025 Earnings Call Transcript - AOL.com
Pacira Biosciences (PCRX) Projects Robust Growth in FY26 with St - GuruFocus
Pacira Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Pacira: Q4 Earnings Snapshot - marketscreener.com
Q4 2025 Pacira Biosciences Inc Earnings Call Transcript - GuruFocus
Pacira BioSciences Inc. (PCRX) Stock Falls on Q4 2025 Earnings - Quiver Quantitative
Pacira BioSciences Q4 Earnings Assessment - Benzinga
BRIEF-Pacira Biosciences FY Adjusted EBITDA USD 186.5 Million Vs. IBES Estimate USD 204 Million - TradingView
Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results - Yahoo Finance
Why (PCRX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Pacira BioSciences, Inc. (PCRX) Stock Analysis: A Healthcare Innovator with 28.58% Potential Upside - DirectorsTalk Interviews
Pacira Biosciences, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Pacira BioSciences, Inc. $PCRX Shares Acquired by Doma Perpetual Capital Management LLC - MarketBeat
Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Can Pacira BioSciences Inc expand its profit margins2025 Valuation Update & Detailed Earnings Play Alerts - baoquankhu1.vn
Pacira Biosciences (PCRX) Securities Lawsuit Dismissed by New Jersey Federal Court - TipRanks
1.15%
3.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):